Fungal infections have emerged as a major global health concern due to their increasing prevalence, high recurrence rate, and growing resistance to conventional antifungal therapies. These infections, commonly known as mycoses, are caused by pathogenic fungi and are broadly classified into superficial, subcutaneous, and systemic infections depending on the depth and site of infection. Superficial fungal infections of the skin, hair, and nails are among the most common infectious diseases worldwide, affecting nearly one-fourth of the global population. Individuals with weakened immune systems, diabetes, prolonged antibiotic therapy, or poor hygiene are at a significantly higher risk of developing fungal infections. Although several antifungal agents are available, conventional topical formulations often fail to provide adequate therapeutic outcomes because of poor drug penetration through the stratum corneum, limited drug retention at the infected site, and the need for repeated application. These limitations necessitate the development of novel drug delivery systems capable of improving skin penetration and enhancing therapeutic efficacy. Flucytosine (5-fluorocytosine) is a well-established antifungal agent with potent activity against Candida and Cryptococcus species. It exerts its antifungal action by inhibiting fungal DNA and RNA synthesis after its intracellular conversion into 5-fluorouracil. Despite its effectiveness, the clinical use of flucytosine is limited due to rapid renal elimination, systemic toxicity, and the possibility of developing drug resistance during prolonged therapy.